ASXL1 Disruption in T Cells for Immunotherapy Enhancement
Summary
The USPTO published patent application US20260091115A1 filed by St. Jude Children's Research Hospital, Inc., covering modified immune effector cells with disrupted ASXL1 genes for enhanced immunotherapy function. The application includes claims for the modified T cells, methods of generating them, and methods for using them in adoptive cell therapy treatments for diseases.
What changed
St. Jude Children's Research Hospital filed patent application US20260091115A1 (Application No. 19112045) on September 15, 2023, published April 2, 2026, disclosing immune effector cells with ASXL1 disruption to enhance immune cell function. The application covers modified T cells and related pharmaceutical compositions for use in adoptive cell therapy, with inventors including Benjamin YOUNGBLOOD, Caitlin ZEBLEY, Tae Gun KANG, and Kirsten Grønbæk. CPC classifications indicate applications in cellular therapy (C12N), protein compositions (C07K), and therapeutic methods.
This patent publication does not impose compliance requirements on third parties. Companies developing CAR-T or other cell therapies should review the claims to assess potential freedom-to-operate implications. No immediate action is required; however, IP counsel may wish to monitor the prosecution of this application for competitive intelligence purposes.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DISRUPTION OF ASXL1 IN T CELLS TO ENHANCE IMMUNOTHERAPY
Application US20260091115A1 Kind: A1 Apr 02, 2026
Assignee
St. Jude Children's Research Hospital, Inc.
Inventors
Benjamin YOUNGBLOOD, Caitlin ZEBLEY, Tae Gun KANG, Kirsten Grønbæk
Abstract
The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and methods for using the modified immune effector cell for treatment of diseases (e.g., adoptive cell therapy).
CPC Classifications
A61K 40/4217 A61K 40/11 A61K 40/31 A61K 40/4205 C07K 14/7051 C07K 16/2866 C07K 16/32 C12N 9/226 C12N 15/11 C12N 15/907 C07K 2317/622 C12N 2310/20
Filing Date
2023-09-15
Application No.
19112045
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.